These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 10229431)

  • 1. Outcome variables in ankylosing spondylitis: evaluation of their relevance and discriminant capacity.
    Calin A; Nakache JP; Gueguen A; Zeidler H; Mielants H; Dougados M
    J Rheumatol; 1999 Apr; 26(4):975-9. PubMed ID: 10229431
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of fatigue in the management of patients with ankylosing spondylitis.
    Dernis-Labous E; Messow M; Dougados M
    Rheumatology (Oxford); 2003 Dec; 42(12):1523-8. PubMed ID: 13130145
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinimetric evaluation of the bath ankylosing spondylitis metrology index in a controlled trial of pamidronate therapy.
    Jauregui E; Conner-Spady B; Russell AS; Maksymowych WP
    J Rheumatol; 2004 Dec; 31(12):2422-8. PubMed ID: 15570645
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical relevance of C-reactive protein in axial involvement of ankylosing spondylitis.
    Dougados M; Gueguen A; Nakache JP; Velicitat P; Zeidler H; Veys E; Calin A
    J Rheumatol; 1999 Apr; 26(4):971-4. PubMed ID: 10229430
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A six-month randomized, controlled, double-blind, dose-response comparison of intravenous pamidronate (60 mg versus 10 mg) in the treatment of nonsteroidal antiinflammatory drug-refractory ankylosing spondylitis.
    Maksymowych WP; Jhangri GS; Fitzgerald AA; LeClercq S; Chiu P; Yan A; Skeith KJ; Aaron SL; Homik J; Davis P; Sholter D; Russell AS
    Arthritis Rheum; 2002 Mar; 46(3):766-73. PubMed ID: 11920413
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis.
    Brandt J; Khariouzov A; Listing J; Haibel H; Sörensen H; Grassnickel L; Rudwaleit M; Sieper J; Braun J
    Arthritis Rheum; 2003 Jun; 48(6):1667-75. PubMed ID: 12794835
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stability of the patient acceptable symptomatic state over time in outcome criteria in ankylosing spondylitis.
    Tubach F; Pham T; Skomsvoll JF; Mikkelsen K; Bjørneboe O; Ravaud P; Dougados M; Kvien TK
    Arthritis Rheum; 2006 Dec; 55(6):960-3. PubMed ID: 17139643
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Measuring disease activity in ankylosing spondylitis: patient and physician have different perspectives.
    Spoorenberg A; van Tubergen A; Landewé R; Dougados M; van der Linden S; Mielants H; van de Tempel H; van der Heijde D
    Rheumatology (Oxford); 2005 Jun; 44(6):789-95. PubMed ID: 15757962
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis.
    Anderson JJ; Baron G; van der Heijde D; Felson DT; Dougados M
    Arthritis Rheum; 2001 Aug; 44(8):1876-86. PubMed ID: 11508441
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of celecoxib, a cyclooxygenase 2-specific inhibitor, in the treatment of ankylosing spondylitis: a six-week controlled study with comparison against placebo and against a conventional nonsteroidal antiinflammatory drug.
    Dougados M; Béhier JM; Jolchine I; Calin A; van der Heijde D; Olivieri I; Zeidler H; Herman H
    Arthritis Rheum; 2001 Jan; 44(1):180-5. PubMed ID: 11212158
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT).
    van der Heijde D; Dijkmans B; Geusens P; Sieper J; DeWoody K; Williamson P; Braun J;
    Arthritis Rheum; 2005 Feb; 52(2):582-91. PubMed ID: 15692973
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index.
    Calin A; Garrett S; Whitelock H; Kennedy LG; O'Hea J; Mallorie P; Jenkinson T
    J Rheumatol; 1994 Dec; 21(12):2281-5. PubMed ID: 7699629
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Double blind, randomised, placebo controlled study of leflunomide in the treatment of active ankylosing spondylitis.
    van Denderen JC; van der Paardt M; Nurmohamed MT; de Ryck YM; Dijkmans BA; van der Horst-Bruinsma IE
    Ann Rheum Dis; 2005 Dec; 64(12):1761-4. PubMed ID: 15901634
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparative study of the usefulness of the Bath Ankylosing Spondylitis Functional Index and the Dougados Functional Index in the assessment of ankylosing spondylitis.
    Spoorenberg A; van der Heijde D; de Klerk E; Dougados M; de Vlam K; Mielants H; van der Tempel H; van der Linden S
    J Rheumatol; 1999 Apr; 26(4):961-5. PubMed ID: 10229428
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis.
    Lukas C; Landewé R; Sieper J; Dougados M; Davis J; Braun J; van der Linden S; van der Heijde D;
    Ann Rheum Dis; 2009 Jan; 68(1):18-24. PubMed ID: 18625618
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Celecoxib is efficacious and well tolerated in treating signs and symptoms of ankylosing spondylitis.
    Barkhuizen A; Steinfeld S; Robbins J; West C; Coombs J; Zwillich S
    J Rheumatol; 2006 Sep; 33(9):1805-12. PubMed ID: 16960941
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The efficacy and tolerability of aceclofenac in the treatment of patients with ankylosing spondylitis: a multicenter controlled clinical trial. Aceclofenac Indomethacin Study Group.
    Batlle-Gualda E; Figueroa M; Ivorra J; Raber A
    J Rheumatol; 1996 Jul; 23(7):1200-6. PubMed ID: 8823693
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of mesalazine (Salofalk) in an open study of 20 patients with ankylosing spondylitis.
    van Denderen JC; van der Horst-Bruinsma I; Bezemer PD; Dijkmans BA
    J Rheumatol; 2003 Jul; 30(7):1558-60. PubMed ID: 12858458
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of methotrexate in ankylosing spondylitis: a randomized, double blind, placebo controlled trial.
    Gonzalez-Lopez L; Garcia-Gonzalez A; Vazquez-Del-Mercado M; Muñoz-Valle JF; Gamez-Nava JI
    J Rheumatol; 2004 Aug; 31(8):1568-74. PubMed ID: 15290737
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improvement in patient-reported outcomes for patients with ankylosing spondylitis treated with etanercept 50 mg once-weekly and 25 mg twice-weekly.
    Braun J; McHugh N; Singh A; Wajdula JS; Sato R
    Rheumatology (Oxford); 2007 Jun; 46(6):999-1004. PubMed ID: 17389658
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.